title: A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
abstract: Capecitabine is a highly active oral fluoropyrimidine that is an attractive alternative to 5-fluorouracil in colorectal cancer treatment. The current study, undertaken in 27 patients with gastrointestinal tumours, aimed to assess the toxicity and potential for significant pharmacokinetic interactions of a combination regimen incorporating capecitabine with 3-weekly irinotecan (XELIRI). Irinotecan (200 and 250 mg m(-2)) was administered as a 90-min infusion on day 1 in combination with escalating capecitabine doses (700-1250 mg m(-2) twice daily) administered on days 2-15 of a 3-week treatment cycle. Pharmacokinetics were characterised on days 1 and 2 of the first two cycles. A total of 103 treatment cycles were administered. The principal dose-limiting toxicities were diarrhoea and neutropenia. Capecitabine 1150 mg m(-2) twice daily with irinotecan 250 mg m(-2) was identified as the maximum-tolerated dose and capecitabine 1000 mg m(-2) with irinotecan 250 mg m(-2) was identified as the recommended dose for further study. Analyses confirmed that there were no significant pharmacokinetic interactions between the two agents. The combination was clinically active, with complete and partial responses achieved in heavily pretreated patients. This study indicates that XELIRI is a potentially feasible and clinically active regimen in patients with advanced gastrointestinal cancer.
authors.affiliation: Institut Claudius Regaud, 20-24, rue du Pont Saint Pierre, Toulouse 31052, France. delord_j@cr.fnclcc.fr
authors.forename: J P
authors.initials: JP
authors.lastname: Delord
authors.forename: J Y
authors.initials: JY
authors.lastname: Pierga
authors.forename: V
authors.initials: V
authors.lastname: Dieras
authors.forename: F
authors.initials: F
authors.lastname: Bertheault-Cvitkovic
authors.forename: F L
authors.initials: FL
authors.lastname: Turpin
authors.forename: F
authors.initials: F
authors.lastname: Lokiec
authors.forename: I
authors.initials: I
authors.lastname: Lochon
authors.forename: E
authors.initials: E
authors.lastname: Chatelut
authors.forename: P
authors.initials: P
authors.lastname: Canal
authors.forename: R
authors.initials: R
authors.lastname: Guimbaud
authors.forename: D
authors.initials: D
authors.lastname: Mery-Mignard
authors.forename: X
authors.initials: X
authors.lastname: Cornen
authors.forename: Z
authors.initials: Z
authors.lastname: Mouri
authors.forename: R
authors.initials: R
authors.lastname: Bugat
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000633:toxicity; D019540:Area Under Curve; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000633:toxicity*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005472:Fluorouracil / Q000031:analogs & derivatives; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D009362:Neoplasm Metastasis; D018579:Patient Selection; D011355:Prodrugs / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity*; D012449:Safety
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D011355:Prodrugs; D003841:Deoxycytidine; D000069287:Capecitabine; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin